Book contents
- Frontmatter
- Contents
- Introduction
- How to use this book
- Abbreviations
- Acknowledgements
- DRUGS: AN A–Z GUIDE
- SHORT NOTES
- Routes of administration
- Loading dose
- Drug metabolism
- Enzyme systems
- Drug excretion
- Drug tolerance
- Drug interactions
- Therapeutic drug monitoring
- Target range of concentration
- Pharmacology in the critically ill
- Cardiopulmonary resuscitation
- Drugs in advanced life support
- Management of acute major anaphylaxis
- Management of severe hyperkalaemia
- Management of malignant hyperthermia
- Sedation, analgesia and neuromuscular blockade
- A practical approach to sedation and analgesia
- Opioid Conversion table
- Management of status epilepticus
- Prevention of delirium tremens and alcohol withdrawal syndrome
- Prevention of Wernicke–Korsakoffsyndrome
- Anti-arrhythmic drugs
- Inotropes and vasopressors
- Bronchospasm
- Anti-ulcer drugs
- Immunonutrition in the ICU
- Corticosteroids
- Short synacthen test
- Bone marrow rescue following nitrous oxide
- Antioxidants
- Post-splenectomy prophylaxis
- Anti-microbial drugs
- Bacterial gram staining
- Antibiotics: sensitivities
- Renal replacement therapy
- Extracorporeal drug clearance: basic principles
- Drug doses in renal failure/renal replacement therapy
- Chemical pleurodesis of malignant pleural effusion
- APPENDICES
- DRUG INDEX
- IV COMPATIBILITY CHART
Bone marrow rescue following nitrous oxide
Published online by Cambridge University Press: 05 November 2014
- Frontmatter
- Contents
- Introduction
- How to use this book
- Abbreviations
- Acknowledgements
- DRUGS: AN A–Z GUIDE
- SHORT NOTES
- Routes of administration
- Loading dose
- Drug metabolism
- Enzyme systems
- Drug excretion
- Drug tolerance
- Drug interactions
- Therapeutic drug monitoring
- Target range of concentration
- Pharmacology in the critically ill
- Cardiopulmonary resuscitation
- Drugs in advanced life support
- Management of acute major anaphylaxis
- Management of severe hyperkalaemia
- Management of malignant hyperthermia
- Sedation, analgesia and neuromuscular blockade
- A practical approach to sedation and analgesia
- Opioid Conversion table
- Management of status epilepticus
- Prevention of delirium tremens and alcohol withdrawal syndrome
- Prevention of Wernicke–Korsakoffsyndrome
- Anti-arrhythmic drugs
- Inotropes and vasopressors
- Bronchospasm
- Anti-ulcer drugs
- Immunonutrition in the ICU
- Corticosteroids
- Short synacthen test
- Bone marrow rescue following nitrous oxide
- Antioxidants
- Post-splenectomy prophylaxis
- Anti-microbial drugs
- Bacterial gram staining
- Antibiotics: sensitivities
- Renal replacement therapy
- Extracorporeal drug clearance: basic principles
- Drug doses in renal failure/renal replacement therapy
- Chemical pleurodesis of malignant pleural effusion
- APPENDICES
- DRUG INDEX
- IV COMPATIBILITY CHART
Summary
• Folic/folinic acid 15 mg IV for 2 days
• Vitamin B12 1 mg IV for 2 days
The use of nitrous oxide for anaesthesia in excess of 2 h inactivates vitamin B 12 and may lead to impaired DNA synthesis and megaloblastic bone marrow haemopoiesis. In fit patients this is of little significance, but in the critically ill it may increase the mortality rate. Haemopoeitic changes induced by nitrous oxide can be reversed by folic/folinic acid. Vitamin B12 is given to replace that which has been inactivated. It is recommended by some authorities that both folic/folinic acid and vitamin B12 should be given to critically ill patients following surgery in which nitrous oxide was used as part of the anaesthetic for >2 hours.
- Type
- Chapter
- Information
- Handbook of Drugs in Intensive CareAn A-Z Guide, pp. 287Publisher: Cambridge University PressPrint publication year: 2014